Tables 9 Effect of δ-tocotrienol on "diseases or functions annotation" section of IPA analysis of total mRNAs of hepatitis C patients
# | Categories | Diseases or Functions Annotation | P-Value | Predicted Activation | Act Z-Score | Molecules | # Molecules |
|---|---|---|---|---|---|---|---|
A | Up-regulated (11) | ||||||
1 | Cell Death and Survival | cell death | 3.94E-21 | Increased | 2.645 | ABCD1,ABL1,ACO2 | 349 |
2 | Cancer, Cell Death and Survival | necrosis of malignant tumor | 4.75E-21 | Increased | 3.412 | ABL1,B2M,BCL2L11 | 76 |
3 | Cellular Function and Maintenance | function of lymphatic system cells | 2.1E-16 | 0.273 | ABL1,ARHGEF, | 60 | |
4 | Cellular Function and Maintenance | function of leukocytes | 1.25E-15 | 0.051 | ARHGEF6,ARRB2,B2M | 77 | |
5 | Gene Expression, Protein Synthesis | translation of mRNA | 1.6E-12 | Increased | 2.941 | BTG2,DNAJC1,EIF2S3 | 36 |
6 | Gene Expression | expression of mRNA | 3.44E-12 | Increased | 2.115 | BTG2,CD47,DNAJC1 | 43 |
7 | Metabolic Disease | glucose metabolism disorder | 2.76E-08 | 1.558 | ABHD16A,ALOX5AP,ANAPC13 | 136 | |
8 | Organismal Survival | organismal death | 0.00000495 | Increased | 11.544 | ABL1,ADORA2A,APRT | 210 |
9 | Cancer, Hematological Disease | lymphoproliferative malignancy | 0.00000592 | 1.725 | ABL1,ADORA2A,AIMP1 | 203 | |
10 | Neurological Disease, Organismal | disorder of basal ganglia | 0.0000781 | 1.538 | ABCD1,ABL1,ADORA2A | 76 | |
11 | Cancer, Organismal Injury | carcinoma | 0.0000854 | 0.711 | ABCD1,ABHD16A,ABL1 | 749 | |
B | Down-regulated (49) | ||||||
12 | Cellular Development, Cellular | proliferation of immune cells | 1.29E-24 | Decreased | -2.128 | ABL1,ADORA2A,ARHGEF6 | 128 |
13 | Cellular Development, Cellular | proliferation of mononuclear leukocytes | 6.29E-24 | Decreased | -2.073 | ABL1,ADORA2A,ARHGEF6 | 123 |
14 | Infectious Diseases | Viral Infection | 6.4E-24 | Decreased | -5.928 | ABL1,ADORA2A,AGO4 | 207 |
15 | Cellular Growth and Proliferation | proliferation of lymphatic system cells | 8.63E-24 | Decreased | -2.019 | ABL1,ADORA2A,ARHGEF6 | 129 |
16 | Immunological Disease | systemic autoimmune syndrome | 2.37E-23 | -0.774 | ABHD16A,ADORA2A,AKR1D1 | 163 | |
17 | Hematological System Development | quantity of mononuclear leukocytes | 6.64E-19 | Decreased | -4.691 | ABL1,ADORA2A,ARHGEF6 | 113 |
18 | Lymphoid Tissue Structure | quantity of lymphatic system cells | 1.46E-18 | Decreased | -4.679 | ABL1,ADORA2A,ARHGEF6 | 115 |
19 | Hematological System Development | quantity of blood cells | 6.22E-16 | Decreased | -4.724 | ABL1,ADD3,ADORA2A | 134 |
20 | Cell-To-Cell Signaling and Interaction | activation of cells | 2E-15 | Decreased | -5.698 | ADORA2A,AFP,ARRB2 | 127 |
21 | Connective Tissue Disorders | inflammation of joint | 2.16E-13 | -1.573 | ABL1,ADORA2A,AKR1D1 | 128 | |
22 | Cardiovascular Disease, Developmental | Diamond-Blackfan anemia | 4.55E-11 | CD52,FLVCR1,RPL11 | 13 | ||
23 | Antimicrobial Response, Inflammatory | antimicrobial response | 8.55E-09 | -1.395 | APOBEC3A,ATG5,BCL10 | 44 | |
24 | Embryonic Development, Hematological | formation of lymphoid tissue | 1.45E-08 | Decreased | -2.618 | ABL1,B2M,BCL2L11 | 48 |
25 | Free Radical Scavenging | metabolism of reactive oxygen species | 1.56E-08 | Decreased | -2.89 | ABL1,ATG5,ATP7A | 63 |
26 | Neurological Disease, Skeletal | neuromuscular disease | 5.12E-07 | -0.200 | ABL1,ADORA2A,ALAS1 | 95 | |
27 | Cell Morphology | morphology of blood cells | 7.37E-07 | ABCD1,ABL1,ADD3 | 52 | ||
28 | Inflammatory Response, Neurological | inflammation of central nervous system | 0.00000109 | -1.099 | ADORA2A,B2M,C3AR1 | 48 | |
29 | Humoral Immune Response, Protein | production of antibody | 0.00000114 | -1.497 | B2M,BCL10,BCL2L11 | 40 | |
30 | Endocrine System Disorders | diabetes mellitus | 0.00000166 | Decreased | -2.058 | ABHD16A,ALOX5AP,ANAPC13 | 110 |
31 | Digestive System Development | morphology of Peyer's patches | 0.00000208 | DDX58,ID2,IGKC | 12 | ||
32 | Cellular Compromise, Inflammatory | degranulation of cells | 0.0000021 | Decreased | -3.08 | C3AR1,C5AR1,CAMP | 31 |
33 | Cell Signaling, Molecular Transport | mobilization of Ca2+ | 0.00000212 | Decreased | -2.95 | ADORA2A,ARRB2,B2M | 42 |
34 | Cell-To-Cell Signaling and Interaction | binding of leukocytes | 0.00000273 | Decreased | -4.799 | ABL1,ADORA2A,ARRB2 | 46 |
35 | Immunological Disease | allergy | 0.00000286 | -1.655 | ABL1,ACO2,ADORA2A | 49 | |
36 | Humoral Immune Response, Protein | quantity of immunoglobulin | 0.00000494 | -1.731 | B2M,BCL10,BCL2L11 | 37 | |
37 | RNA Post-Transcriptional Modification | processing of RNA | 0.0000059 | -0.670 | ADAT1,AFF2,CELF1 | 36 | |
38 | Hematological System Development | quantity of thymocytes | 0.00000592 | Decreased | -3.599 | ABL1,B2M,BCL10 | 30 |
39 | Immunological Disease | abnormal morphology of immune | 0.00000593 | ABCD1,ABL1,B2M | 37 | ||
40 | Cancer, Hematological Disease | mature B-cell lymphoma | 0.00000888 | ABL1,B2M,BCL10 | 38 | ||
41 | Digestive System Development | abnormal morphology of Peyer's | 0.00000906 | DDX58,ID2,IGKC | 11 | ||
42 | Lipid Metabolism, Small Molecule | synthesis of eicosanoid | 0.00000989 | Decreased | -3.209 | ALOX5AP,ATP5J,C5AR1 | 29 |
43 | Cellular Growth and Proliferation | expansion of cells | 0.0000113 | -0.717 | ADORA2A,B2M,BMI1 | 37 | |
44 | Lipid Metabolism, Small Molecule | synthesis of leukotriene C4 | 0.0000148 | Decreased | -2.753 | ALOX5AP,C5AR1,COTL1 | 8 |
45 | Gene Expression | activation of DNA endogenous | 0.000016 | Decreased | -3.846 | ARRB2,ATF4,BMI1 | 111 |
46 | Antigen Presentation, Inflammatory | antigen presentation | 0.0000715 | -1.556 | ARL8B,CD74,CST3 | 14 | |
47 | Cell Death and Survival, Organismal | cell death of kidney cells | 0.0000715 | -1.863 | ATG5,ATP1A1,BCL10 | 39 | |
48 | Cellular Movement, Hematological | chemotaxis of granulocytes | 0.0000723 | Decreased | -2.235 | ADORA2A,BST1,C3AR1 | 24 |
49 | Cancer, Hematological Disease | large-cell lymphoma | 0.0000741 | B2M,BCL2L11,CAMLG | 34 | ||
50 | Cell-To-Cell Signaling and Interaction | binding of mononuclear leukocytes | 0.0000753 | Decreased | -3.212 | CD47,CD48,CD58 | 25 |
51 | Cellular Movement, Embryonic | chemotaxis of embryonic cell lines | 0.0000767 | Decreased | -2.587 | ARRB2,CAMP,CXCL1 | 7 |
52 | Cellular Movement, Hair and Skin | chemotaxis of epithelial cell lines | 0.0000767 | Decreased | -2.587 | ARRB2,CAMP,CXCL1 | 7 |
53 | Cell Death and Survival, Skeletal | cell death of smooth muscle cells | 0.0000775 | -0.332 | ARRB2,CAMP,CASP3 | 16 | |
54 | Cell Death and Survival | cell viability of phagocytes | 0.0000775 | Decreased | -2.939 | BCL2A1,CD48,CEBPB | 16 |
55 | Cell Death and Survival | killing of lymphatic system cells | 0.0000789 | Decreased | -2.016 | BCL2L11,CD47,CD48 | 10 |
56 | Cell Death and Survival | cell viability of mononuclear leukocytes | 0.0000805 | Decreased | -3.491 | ATG3,BCL10,BCL2L11 | 25 |
57 | Cellular Development, Cellular Growth | differentiation of myeloid leukocytes | 0.0000809 | -1.081 | ABL1,CAMP,CD47 | 31 | |
58 | Cell-To-Cell Signaling and Interaction | binding of lymphatic system cells | 0.0000847 | Decreased | -3.360 | CD47,CD48,CD58 | 23 |
59 | RNA Post-Transcriptional Modification | unwinding of mRNA | 0.000086 | EIF4A1,EIF4A2,EIF4B | 3 | ||
60 | Cell Death and Survival, Organismal | cell death of epithelial cells | 0.000136 | -1.105 | ARRB2,ATG5,BCL10 | 51 | |